Gilead Sciences LLC

Gilead holds sole rights for clinical development and potential commercialisation of the compounds developed under the deal. Credit: JHVEPhoto/Shutterstock. Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop new small molecule therapies. The deal will utilise the advanced AI technologies of Genesis to generate therapeutic candidates for targets chosen by Gilead. Genesis’ field-leading AI platform, Genesis Exploration of Molecular Space (GEMS) will be used in the partnership to aid in creating and streamlining molecules for the Gilead-chosen targets. The collaboration will focus on preclinical research, with Gilead holding sole rights for the clinical development and potential commercialisation of the compounds developed. Gilead Sciences Research executive vice-president Flavius Martin stated: “The use of generative AI in drug development, enabled by people, science and other new technology, has shown potential to accelerate the discovery of molecules for challenging targets. See Also: NanoSyrinx secures funds to develop biologic therapeutics FDA grants breakthrough therapy status to Arrowhead’s plozasiran “We look forward to working with Genesis to apply their AI platform to discover and advance novel therapies that may address significant unmet patient needs . ” Genesis is entitled to receive $35m in upfront payment for three targets, with options for Gilead to nominate additional targets for a fee. Genesis also stands to gain further financial rewards through preclinical, development, regulatory and commercial milestones, as well as royalty payments on net product sales. Genesis founder and CEO Evan Feinberg stated: “Many promising protein targets have a paucity of relevant training data, which makes it difficult to apply off-the-shelf machine learning methods. “We have designed our physical AI platform to address this issue and enable drug discovery campaigns for difficult targets. Genesis is thrilled to combine our expertise in generative AI and drug discovery with Gilead’s deeply experienced research and development teams, with the shared goal of creating breakthrough therapies for patients.” Genesis had previously secured more than $300m in funding to create a pipeline, targeting high-impact medical conditions. The latest development comes after Gilead partnered with PANTHERx Rare to distribute LIVDELZI , a treatment for adults with primary biliary cholangitis.

Gilead Sciences, a leading global biopharmaceutical company, has actively pursued a series of large-scale merger and acquisition (M&A) strategies over the past five years, aiming to further expand its market presence in areas such as immuno-oncology and liver diseases through investment and acquisitions. However, as the old saying goes, "Nothing is known to be difficult until it has been experienced," these seemingly brilliant acquisition projects have encountered numerous twists and turns in their actual implementation.   For example, in March 2020, Gilead acquired FortySeven Inc. for a staggering $4.9 billion in cash, with the primary target being FortySeven's flagship product, Magrolimab. As an antibody drug targeting the CD47 molecule, Magrolimab had shown promising potential in early clinical trials and had even been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in September of the same year, further raising market expectations for the drug.   However, the good times did not last long. In the subsequent Phase III ENHANCE trial, Magrolimab's efficacy failed to be validated. Even more worryingly, the drug may have an adverse effect on untreated high-risk myelodysplastic syndrome patients. This result was undoubtedly a major blow to Gilead, and it also means that the development of Magrolimab may come to an end.   Reviewing Gilead's acquisition history over the past five years, it is clear that the company has invested heavily. In addition to FortySeven, Gilead has also spent $11 billion to acquire Pharmasset, $11.9 billion to acquire Kite Pharma, and $21 billion to acquire Immunomedics. However, these seemingly prestigious acquisitions have not brought the expected success to Gilead. As of now, the returns on these investments are not ideal, and have even put the company's financial situation under some pressure.   This series of setbacks has undoubtedly become a major "pain point" for Gilead Pharmaceuticals in recent years. The large-scale capital operations have not led to the expected success, but have instead plunged the company into difficulties. This has also led to external questioning of whether Gilead is overly dependent on the M&A expansion development path. After all, while acquisitions can quickly expand a company's market share and product lines, they also carry enormous financial risks and integration difficulties.   Looking deeper, Gilead Pharmaceuticals has also revealed some underlying concerns in its development process. Firstly, the over-reliance on acquisitions. Although acquisitions can quickly expand the company's scale and market influence, over-reliance on acquisitions can also easily lead the company to neglect its own research and development capabilities and innovation capabilities. Secondly, Gilead also has certain "weaknesses" in its R&D pipeline. Although the company is involved in multiple areas, it does not have many truly core competitive products. This has to some extent limited the company's long-term development.   Faced with the current difficulties and challenges, Gilead Pharmaceuticals needs to seriously reflect on and adjust its own development strategy. First, the company should focus more on its own research and development capabilities and innovation capabilities, and increase investment and support in the R&D field. At the same time, the company also needs to more carefully evaluate the risks and returns of acquisition projects, and avoid over-relying on acquisition expansion as a development path. In addition, the company also needs to strengthen the optimization and upgrading of existing products, and enhance the competitiveness and market position of its products.   In summary, although Gilead Pharmaceuticals has achieved certain results in the past few years, it also faces many challenges and difficulties. Whether the company can find a new breakthrough, get out of the current predicament, and achieve sustainable development in the future remains to be seen.

SAN FRANCISCO, Oct. 9, 2023 /PRNewswire/ -- Roberts Law Firm US, PC and NastLaw LLC announce that a proposed settlement has been reached in a class action lawsuit (KPH Healthcare Services, Inc. v. Gilead Sciences, Inc., No. 20-cv-06961-EMC (N.D. Cal.) (coordinated with In re HIV Antitrust Litigation (formerly called Staley v. Gilead Sciences, Inc.), No. 3:19-cv-02573-EMC (N.D. Cal.)). The lawsuit alleges that Gilead engaged in a variety of alleged anticompetitive conduct in violation of federal antitrust laws that caused direct purchasers to pay too much for certain drugs used to treat and prevent HIV (Truvada, Atripla, and their generic equivalents). The Settlement resolves the claims against Gilead; a prior settlement resolved claims against BMS. Gilead denies any wrongdoing. No court or other authority has found that Gilead engaged in any wrongdoing. The proposed Settlement generally includes entities that purchased Truvada, Atripla, or any of their generic equivalents directly from Gilead or any generic drug manufacturer from February 1, 2018 until September 27, 2022. Under the Settlement, Gilead will pay $246,750,000 into a Settlement Fund to settle all claims in the lawsuit. If you are a Class Member and want to get paid, you must submit a Claim Form by January 1, 2024, either online at or by mail. If the Court approves the Settlement, claims will be paid after any appeals. Class Counsel will seek reimbursement for litigation costs and expenses, attorneys' fees, and a class representative service award. If approved, these amounts will be paid from the Settlement Fund. If you are a Class Member, you can write to the Court about what, if anything, you do not like about the Settlement. The deadline to do so is December 28, 2023. Descriptions about the effects of these options and instructions on how to exercise them are available in the detailed notice available at . The Court scheduled a hearing for January 18, 2024 at 1:30 p.m. Pacific Time to consider whether the Settlement and allocations are fair, reasonable, and adequate, as well as any objections and any requests for reimbursement of costs and expenses, attorneys' fees, and a class representative service award. You do not need to attend, but you or your attorney may do so at your own expense. See the detailed notice available at for the hearing location, where to find out if the date or time changes, and what you must do if you or your attorney wish to speak at the hearing. For more information, visit or call (501) 821-5575. SOURCE Roberts Law Firm US, PC and NastLaw LLC